Get the Stockscreener App
33.16
0.73%
0.24
Alamar Biosciences Inc stock is traded at $33.16, with a volume of 161.14K.
It is up +0.73% in the last 24 hours and up +22.59% over the past month.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
See More
Previous Close:
$32.92
Open:
$33.81
24h Volume:
161.14K
Relative Volume:
0.52
Market Cap:
$2.30B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+16.51%
1M Performance:
+22.59%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$32.61
$33.81
1-Week Range:
$27.72
$38.54
52-Week Range:
$18.84
$38.54
Alamar Biosciences Inc Stock (ALMR) Company Profile
Name
Alamar Biosciences Inc
Sector
Industry
Phone
510-626-9888
Address
47071 BAYSIDE PARKWAY, FREMONT
Compare ALMR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMR
Alamar Biosciences Inc
|
33.16 | 2.30B | 0 | 0 | 0 | 0.00 |
ABT
Abbott Laboratories
|
111.25 | 191.92B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
339.21 | 133.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
91.27 | 116.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.83 | 74.52B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
91.60 | 53.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
Alamar Biosciences Inc Stock (ALMR) Latest News
Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument - Seeking Alpha
Alamar Biosciences (ALMR) Stock Price Jumps As Margin Gains Meet Loss Pressure - Sahm
Alamar Biosciences (ALMR): Yuling Luo discloses 6.4% beneficial ownership stake - Stock Titan
Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Alamar Biosciences, Inc. Common Stock (NASDAQ: ALMR) Stock Price, News & Analysis - kalkine.ca
Analysts Offer Insights on NA Companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ) and Amentum Holdings, Inc. (AMTM) - The Globe and Mail
Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up - TechStock²
Alamar Biosciences (ALMR): Qiming funds report over 10% ownership stake - Stock Titan
Alamar Biosciences Q2 Results: Revenue Rises 82% To $29.4 Million - scanx.trade
Stifel raises Alamar Biosciences stock price target on earnings beat By Investing.com - Investing.com Canada
Alamar Biosciences Reports Q2 2026 Financial Results in Form 10-Q Filing - Kalkine Media
ALAMAR BIOSCIENCES INC : STIFEL RAISES TARGET PRICE TO $32 FROM $28 - Bitget
Alamar Biosciences Q2 2026 Earnings Call Transcript - MarketBeat
Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $33.4, Implies 19% Upside - TradingView
Alamar Biosciences, Inc. 2Q 2026: Revenue $29.4M, EPS $(0.22) — 10-Q Summary - TradingView
Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ... - Yahoo Finance Singapore
Alamar Biosciences (ALMR) Stock Trades At A Premium To Its Sales - Yahoo Finance
Alamar Biosciences to report Q2 2026 results on August 10, 2026 - scanx.trade
Form 8K Alamar Biosciences For: 10 August By Investing.com - Investing.com Nigeria
Alamar Biosciences Q2 Earnings Call Highlights - MarketBeat
Alamar Biosciences Q2 revenue surges 82%, led by consumable demand - scanx.trade
Alamar Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Alamar Biosciences posts strong Q2 2026 revenue growth - Investing.com
Alamar Biosciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALMR) 2026-08-10 - Seeking Alpha
Alamar Biosciences expands proteomics partnership by 86,000 samples - Investing.com Australia
ALAMAR BIOSCIENCES ($ALMR) Releases Q2 2026 Earnings - quiverquant.com
Alamar: Q2 Earnings Snapshot - Yahoo Finance
Earnings Flash (ALMR) Alamar Biosciences Posts Q2 Loss Per Share $0.22, Vs. FactSet Est of $0.31 Loss - Moomoo
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance - The Manila Times
Earnings Flash (ALMR) Alamar Biosciences, Inc. Reports Q2 Revenue $29.4M, Vs. FactSet Est of $25.9M - Moomoo
Alamar Biosciences, Inc. Expands Global Partnership with Alzheimer?s Disease Data Initiative and Gates Ventures - marketscreener.com
Alamar Biosciences (ALMR) Introduced Its NULISAseq Immune 340 Panel - Sahm
Alamar Biosciences Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView
Alamar Biosciences, Inc. (ALMR) stock price, news, quote and history - Yahoo Finance Australia
Alamar Biosciences launches immune profiling panel for research By Investing.com - Investing.com Nigeria
One sample, about 340 immune proteins: Alamar’s new panel - Stock Titan
Alamar Biosciences Inc. (ALMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Alamar Biosciences, Inc. Revenue Breakdown – NASDAQ:ALMR - TradingView
Alamar Biosciences, Inc. (ALMR) Stock Price, News, Quote & History - Yahoo! Finance Canada
ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease - Yahoo Finance
Alamar Biosciences, Inc. (ALMR) Price Book Value - Zacks Investment Research
symbol__ Stock Quote Price and Forecast - CNN
Alamar Biosciences (NASDAQ: ALMR) adjusts board after director death - Stock Titan
This company just filed for an IPO three months after its parent company went public - The Business Journals
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 - The Manila Times
Alamar Biosciences Sets Aug. 10 Results Webcast; Replay to Follow - Stock Titan
IPOs juice biotech real estate (if only a little), but vacancy still climbs and lease rates tumble - The Business Journals
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases - Indovizka.com
Alamar Biosciences 與多間頂尖研究大學合作啟動全國計劃，旨在推動神經退行性疾病相關的血漿生物標記研究 - GlobeNewswire Inc.
BofA Securities Adjusts Alamar Biosciences Price Target to $30 From $27 - Moomoo
Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $30.6, Implies 8% Upside - TradingView
Alamar Biosciences Inc Stock (ALMR) Financials Data
There is no financial data for Alamar Biosciences Inc (ALMR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.08%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):